SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced it has acquired ABBIE, a world-class gene-editing platform that can deliver genetic payloads using non-viral vectors. Through this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023, which is expected to grow to $10.8 billion by 2028 at a 15% CAGR. (Source: 2023, Marketsandmarkets.com.) According to the announcement, ABBIE uses targeted integration to insert larger DNA sequences (aka, genetic payload), including full genes, into a desired loci of the target cell’s genome. ABBIE will enable the editing of genes of a large number of cell types at different stages of their life cycles, overcoming the limitations of current cell editing and engineering technologies. “ABBIE is a platform tool that delivers genes of interest for clinical trials,” said David Aguilar, PhD, SOHM’s COO who is leading ABBIE’s development. “Compared to other gene-editing technologies, ABBIE has achieved the same level of progress with much less R&D spending. Our strategic partnerships and capital management have enabled us to streamline development and expedite our commercialization.”
To view the full press release, visit https://ibn.fm/NhtRh
About SOHM, Inc.
SOHM is a growing generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that aims to build continuous growth. SOHM manufacturing and marketing targets rapidly growing healthcare segments such as nutraceuticals, cosmeceuticals and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India and strategic alliances with U.S. manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and were introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America and Southeast Asia. To learn more about the company, visit www.SOHM.com.
NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
